Amgen stock climbs as obesity drug research boosts future pipeline

Traders Union
All News
Financial News
Amgen gains 3.09% to $338.42 today

Highlights

Amgen secured European approval for Imdelltra, rapidly expanding oncology market access for late-stage small cell lung cancer treatment.
Institutional investor inflows surged, with BNP Paribas raising its Amgen holdings by 218.2%, reflecting reinforced confidence in the company.
AMGN shows moderate short- and long-term support, but technicals signal weak momentum and likely sideways trading between $330 and $346.

European approval and fund inflows boost stock amid obesity pipeline growth

Amgen received European Commission approval for Imdelltra (tarlatamab) as a late-line therapy for adults with extensive-stage small cell lung cancer previously treated with platinum-based chemotherapy, granting immediate access to a new market and expanding its oncology portfolio (gurufocus.com). Fresh inflows from institutional investors were reported by MarketBeat, as CIBC Asset Management and BNP Paribas increased their holdings in the company by 12.2% and 218.2%, respectively, while Bridges Investment Management trimmed its position slightly. The Atlantic highlights Amgen's active work on obesity treatments, adding depth to its late-stage pipeline and aligning with long-term market demand for weight-management therapies.

Mixed momentum after gap open as technical signals diverge at resistance

Technically, $338.42 places AMGN above the SMA-20 ($332.62) and SMA-200 ($328.62), but just beneath the SMA-50 ($341.06). The Ichimoku Kijun line at $335.03 serves as immediate support, while resistance is seen at the SMA-50 level. On the momentum front, the MACD indicates strong selling pressure, whereas the ADX points to a weak and indecisive trend. Both RSI and CCI remain in sell territory with no clear oversold signal, Stoch RSI is neutral, and BBP's deeply negative value underscores recent seller dominance. The technical picture is mixed, with divergences between oscillators and moderate volatility after a gap higher at the open.

Limited upside seen as rangebound trade persists unless momentum shifts

Over the coming week, AMGN is likely to trade within a typical volatility band between $330 and $346. The probability of price appreciation above $346 remains low, currently estimated at under 20%. The base-case scenario is a sideways movement inside this corridor, with a move above $346 opening the way for further gains if buyers take control, while a break below $330 could expose the stock to additional weakness should negative momentum persist.

Anton Kharitonov, analyst at Traders Union, sees mixed signals for Amgen at current levels. He notes positive institutional inflows and regulatory progress, but technical momentum and oscillators remain weak. The analyst believes the base case is sideways trading between $330 and $346, with limited breakout odds. "Until AMGN clears $346 on volume, I view near-term rallies as vulnerable to profit-taking," he says.

Earlier, analysts noted that Amgen was consolidating within a stable long-term trend despite near-term technical uncertainty. The latest move above major averages, combined with institutional inflows and regulatory momentum, suggests traders should now watch for a potential shift in sentiment—with $346 serving as a critical resistance level for confirmation of any sustained upside.

Source of Data: AMGN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.